Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MENOPUR vs A.P.L.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Induction of ovulation in patients with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Off-label: Treatment of male hypogonadotropic hypogonadism (in combination with human chorionic gonadotropin)
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Metabolism is not fully characterized; renally excreted as intact protein.
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Approximately 10-20% bound to plasma proteins, primarily albumin.
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
Subcutaneous or intramuscular: Approximately 70-80% due to partial local degradation; oral bioavailability is negligible (<1%).
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to limited data, consider risk of fluid retention.
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) as metabolism is hepatic; use with caution in Child-Pugh class B.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Not indicated; no established pediatric dosing.
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
Not indicated for geriatric patients; no dosing recommendations.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
MENOPUR should only be used by physicians who are experienced in infertility diagnosis and management. Use may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and result in pulmonary embolism, stroke, ovarian torsion, or death. Use should be avoided in women with a high baseline FSH level indicating primary ovarian failure.
No black box warning.
Ovarian Hyperstimulation Syndrome (OHSS) - risk minimized by monitoring estradiol levels and ultrasound; discontinue if severe.,Multiple pregnancy - high risk; counseling is required.,Ovarian enlargement - usually resolves without treatment.,Pulmonary embolism and arterial thromboembolism - especially in severe OHSS.,Ovarian torsion - consider in patients with severe OHSS.,Ectopic pregnancy - increased risk in patients with tubal disease.,Congenital malformations - incidence similar to natural conception.,Ovarian neoplasms - no definitive causal link, but caution.
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
Hypersensitivity to menotropins or any component.,High baseline FSH indicating primary ovarian failure.,Uncontrolled thyroid or adrenal dysfunction.,Organic intracranial lesion (e.g., pituitary tumor).,Abnormal uterine bleeding of undetermined origin.,Ovarian cysts or enlargement of undetermined origin (not due to PCOS).,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine).,Pregnancy and lactation.
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
No clinically relevant food interactions have been reported. Patients should maintain a normal balanced diet. Grapefruit and grapefruit juice are not known to interact with menotropins. No restriction on caffeine or dairy products.
No known food interactions. Avoid alcohol during treatment.
Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects, congenital heart defects, and multiple anomalies, likely related to the underlying infertility and assisted reproductive technology rather than direct teratogenicity. Second and third trimester risks include preterm labor, low birth weight, and perinatal mortality due to multiple gestation and ovarian hyperstimulation syndrome (OHSS).
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
Menotropins are not indicated during lactation due to lack of data. It is unknown if menotropins are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during therapy. M/P ratio is unknown.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
Menopur is contraindicated during pregnancy. If inadvertent exposure occurs, no dose adjustment is applicable as therapy is discontinued upon pregnancy confirmation. Pharmacokinetic changes in pregnancy (increased plasma volume, altered hormone levels) are not relevant since the drug is not used during gestation.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
MENOPUR (menotropins) is a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) used for ovulation induction and controlled ovarian stimulation. Monitor ovarian response with ultrasound and estradiol levels to minimize risk of ovarian hyperstimulation syndrome (OHSS). Adjust dose based on antral follicle count and prior response. For IVF, concomitant gonadotropin-releasing hormone (Gn RH) antagonist or agonist is typically used to prevent premature LH surge. Administer intramuscularly or subcutaneously; reconstitute immediately before use. Multifetal pregnancy rates are high; counsel patients accordingly.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
MENOPUR is a hormone injection used to help your ovaries produce multiple eggs. It is given as a shot under the skin or into a muscle. Your doctor will show you how to prepare and inject the medication. Do not shake the vial after mixing. Use each vial only once and discard any unused medicine.,Common side effects include injection site reactions (pain, redness, swelling), ovarian enlargement, abdominal discomfort, and mood swings. Serious risks include ovarian hyperstimulation syndrome (OHSS) with symptoms like sudden severe abdominal pain, nausea, vomiting, and rapid weight gain. Notify your doctor immediately if you experience these.,You will have frequent blood tests and vaginal ultrasounds to monitor your response. Stick to the schedule and do not change doses without consulting your doctor.,There is a high chance of multiple pregnancy (twins, triplets, etc.). Discuss the risks and implications with your doctor.,Avoid alcohol and smoking during treatment. No specific food restrictions, but maintain a balanced diet to support overall health.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MENOPUR vs A.P.L., answered by our medical review team.
MENOPUR is a Gonadotropin that works by Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.. A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MENOPUR and A.P.L. depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MENOPUR is: 225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.. The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MENOPUR and A.P.L. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MENOPUR is classified as Category C. Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects. A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.